Chemically Initiated Bone Cement

Brief Description: A biocompatible polymer bone cement with numerous advantages over the currently used polymethyl methacrylates. Uses: Bone repair, orthopedic surgeries, implants, etc. Advantages:

Biocompatible
Lower exotherm
High strength
Low shrinkage
Detailed Description:
Currently available commercial bone cement is based on polymethyl methacrylates and has several disadvantages including toxicity, lack of bioactivity, volumetric shrinkage, tissue necrosis, and the generation of heat upon polymerization. Due to these high temperatures produced during polymerization, antibiotic treatment with bone cement is very limited. Only tobramycin, gentamycin, and vancomycin are heat-stable and can survive the high temperatures during the polymerization of PMMAs.

Our chemically initiated cement is composed primarily of a monomer that has already proven very effective in commercial dental composites. Our extensive testing of this new cement has found that this system is biocompatible, has a peak exotherm that is below 45 degrees C, has low shrinkage, and has excellent mechanical properties. This system provides a biocompatible alternative to PMMA-based bone cement while maintaining good mechanical properties.

Contact Information:

Name: Eric W. Anderson

Title: Director, UMKC Office of Technology Commercialization

Department: Office of Technology Commercialization

Email: ericwa@umkc.edu

Phone: 816-235-5091

Address: 4747 Troost Room 120 Kansas City, Missouri 64110